@article{e5169fd95736411ebe2e3a83d9bc27cf,
title = "Supraspinal μ2-opioid receptors mediate spinal/supraspinal morphine synergy",
abstract = "TRIMU-5 (Tyr-D-Ala-Gly-NHC2H4CH(CH3)2) is a potent μ2-opioid agonist/μ1-opioid antagonist. A supraspinal dose (0.5 μg i.c.v.) of TRIMU-5 which is not analgesic when given alone antagonizes the analgesia produced by intracerebroventricular (i.c.v.) morphine, a μ1 action. In contrast, in a synergy model consisting of the simultaneous administration of intrathecal morphine (0.1 μg) with multiple doses of i.c.v. morphine, the same supraspinal TRIMU-5 dose (0.5 μg i.c.v.) enhances analgesia. Supraspinal TRIMU-5 also potentiates spinal morphine directly, shifting its dose-response to the left. These results imply that within the brainstem μ1 receptors mediate supraspinal analgesia while μ2 receptors mediate the synergy with spinal μ systems.",
keywords = "Analgesia, Morphine, μ-Opioid receptors",
author = "Pick, \{Chaim G.\} and Bernard Roques and Gilles Gacel and Pasternak, \{Gavril W.\}",
year = "1992",
month = sep,
day = "22",
doi = "10.1016/0014-2999(92)90761-R",
language = "אנגלית",
volume = "220",
pages = "275--277",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier B.V.",
number = "2-3",
}